Dr. Sonia Macieiewski (R) and Dr. Nita Patel, Director of Antibody discovery and Vaccine development, look at a sample of a respiratory virus at Novavax labs in Rockville, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19.
Andrew Caballero-Reynolds | AFP | Getty Images
Biotech firm Novavax said Thursday that its coronavirus vaccine was more than 89% effective in protecting against Covid-19 in its phase three clinical trial conducted in the United Kingdom.
The results were based on 62 confirmed Covid-19 infections among the trial’s 15,000 participants. The company said 56 cases were observed in the placebo group versus 6 cases observed in the group that received its vaccine. That resulted in an estimated vaccine efficacy of 89.3%, it said.
Shares of the company were down more than 14% in after-hours trading.
With the results, the company “has the potential to play an important role in solving this global public health crisis,” Novavax CEO Stanley Erck said in a statement. “We look forward to continuing to work with our partners, collaborators, investigators and regulators around the world to make the vaccine available as quickly as possible.”
This is a developing story. Please check back for updates.